Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.
Aroa Biosurgery Ltd has applied to the ASX for quotation of 426,457 new fully paid ordinary shares, issued on 9 April 2026 following the exercise or conversion of existing options or other convertible securities. The additional shares will be listed under the ticker ARX, modestly expanding the company’s quoted share capital and reflecting ongoing utilisation of its equity-based instruments by holders.
The move signals continued engagement with the company’s capital structure and may slightly increase liquidity in Aroa Biosurgery’s stock on the ASX. While the issuance is relatively small in scale, it underscores the role of equity incentives and convertible securities in the company’s financing and shareholder alignment strategy.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Ltd is a medical technology company listed on the ASX under the code ARX. It develops and commercialises biosurgical products, focusing on advanced soft-tissue repair and regenerative healing solutions for healthcare providers and patients in surgical and wound care markets.
Average Trading Volume: 126,888
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$186.6M
For an in-depth examination of ARX stock, go to TipRanks’ Overview page.